Institutional Investors Lead Shift in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) Sentiment

Sentiment for Oncomed Pharmaceuticals Inc (NASDAQ:OMED)

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) institutional sentiment decreased to 0.96 in 2018 Q2. Its down -0.21, from 1.17 in 2018Q1. The ratio worsened, as 22 active investment managers increased and started new holdings, while 23 sold and reduced positions in Oncomed Pharmaceuticals Inc. The active investment managers in our partner’s database now have: 17.82 million shares, down from 18.39 million shares in 2018Q1. Also, the number of active investment managers holding Oncomed Pharmaceuticals Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 17 Increased: 14 New Position: 8.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $37.86 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It has a 6.36 P/E ratio. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

The stock decreased 3.91% or $0.0399 during the last trading session, reaching $0.9801. About 1.47M shares traded or 670.97% up from the average. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 39.47% since December 8, 2017 and is downtrending. It has underperformed by 55.09% the S&P500.

Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on March, 14. They expect $-0.22 earnings per share, down 188.00 % or $0.47 from last year’s $0.25 per share. After $0.16 actual earnings per share reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -237.50 % negative EPS growth.

Bvf Inc Il holds 0.92% of its portfolio in OncoMed Pharmaceuticals, Inc. for 4.10 million shares. Perceptive Advisors Llc owns 2.62 million shares or 0.16% of their US portfolio. Moreover, Birchview Capital Lp has 0.15% invested in the company for 98,689 shares. The New York-based Kazazian Asset Management Llc has invested 0.04% in the stock. Cannell Peter B & Co Inc, a New York-based fund reported 303,071 shares.

Since January 1, 0001, it had 0 insider buys, and 10 selling transactions for $28,990 activity.

More notable recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: Seekingalpha.com which released: “Is OncoMed A Contrarian Buy? – Seeking Alpha” on May 25, 2017, also Seekingalpha.com with their article: “Buy Shares Of This Overlooked Biotech With Catalysts – Seeking Alpha” published on September 27, 2016, Bizjournals.com published: “Paul Hastings lands at startup aimed at cancer’s ‘natural killer’ – San Francisco Business Times” on February 19, 2018. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were released by: Globenewswire.com and their article: “OncoMed Announces Departure of Chief Medical Officer – GlobeNewswire” published on December 05, 2016 as well as Globenewswire.com‘s news article titled: “OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights – GlobeNewswire” with publication date: May 08, 2018.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.